<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02764515</url>
  </required_header>
  <id_info>
    <org_study_id>Chenliji001</org_study_id>
    <nct_id>NCT02764515</nct_id>
  </id_info>
  <brief_title>Kunxian for the Treatment of Rheumatoid Arthritis</brief_title>
  <official_title>Comparison of the Efficacy and Safety of Kunxian Capsule and Methotrexate for the Treatment of Rheumatoid Arthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese SLE Treatment And Research Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>CHENLIJI Pharmaceutical Company,Guangzhou Pharmaceutical Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>CHINESE RHEUMATISM DATA CENTER</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Chinese SLE Treatment And Research Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, randomized, double blind, double-dummy and controlled clinical trial
      aimed to compare the clinical efficacy and safety of Kunxian Capsule, a compound of Chinese
      traditional medicine, and the active comparator,Methotrexate for the treatment of rheumatoid
      arthritis. The primary end-point is that Kunxian Capsule is not inferior to Methotrexate both
      in efficacy and safety.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, multicenter, randomized, double blind, double-dummy and controlled
      clinical trial.The goal is to compare the clinical efficacy and safety of Kunxian Capsule, a
      compound of 4 ingredients of Chinese herb-derived medication, and the active comparator,
      Methotrexate for the treatment of mild to moderate active rheumatoid arthritis.This study is
      basically non-inferiority in design, so 428 subjects will be enrolled. All subjects need to
      fulfill the inclusion criteria and without exclusion criteria. Subjects are randomized into
      the Kunxian Capsule treatment group and Methotrexate treatment group.The dosage of Kunxian
      Capsule used in this study is 0.6g twice daily and the methotrexate dosage is 10mg per week.
      All subjects will take the medication for 24 weeks. Diclofenic is used as the salvage therapy
      in case patients experience joint pain. The primary end-point is the proportion of patients
      who could achieve disease remission or low disease activity treated with Kunxian Capsule and
      Methotrexate. All patients will be followed at week 2,4,12 and 24 after screening. Baseline
      information for disease activity measures such as DAS28 score,CDAI score, SDAI score, ACR20,
      ACR50, ACR70 improvement, HAQ score, patient's VAS score for pain, and lab tests such as CRP,
      ESR, RF, CCP, blood and urine routine tests, liver as well as renal function tests were
      collected and recorded. All these measures are performed at each follow-up visit except RF
      and CCP. In addition, any adverse events or withdrawal happened during each visit will be
      recorded for data analysis.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2015</start_date>
  <completion_date type="Anticipated">November 2017</completion_date>
  <primary_completion_date type="Anticipated">September 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients with ACR 20/50/70</measure>
    <time_frame>24 weeks from baseline</time_frame>
    <description>the percentage of patients who have ACR 20,50 and 70 treatment response after treated with Kunxian Capsule and Methotrexate for 24 weeks</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients whose DAS28 score less than 2.6 or 3.2 after treated with Kunxian Capsule and Methotrexate</measure>
    <time_frame>24 weeks from baseline</time_frame>
    <description>Percentage of patients whose DAS28 could be lower than 3.2 or 2.6 after treated with Kunxian Capsule and Methotrexate for 24 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with adverse events in the Kunxian Capsule treatment group</measure>
    <time_frame>24 weeks from baseline</time_frame>
    <description>The adverse events profile such as gastrointestinal tract adverse events, the percentage of patients with gonodal gland toxicities, liver function abnormalities, hematological abnormalities,skin rashes etc in patients treated with Kunxian Capsule will be analyzed and compared with the adverse events in patients treated with Methotrexate during the same time period.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">428</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Kunxian capsule group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention:
Drug: Kunxian 2 capsules BID taken by mouth for 24 weeks. Kunxian capsule is composed of 4 ingredients: Tripterygium wilfordii Hook F 300mg, extracts from Gouqizi,Tusizi and yinyanghuo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Methotrexate group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intervention:
Drug: Methotrexate tablet 10mg taken by mouth every week for 24 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Kunxian Capsule</intervention_name>
    <description>Patients in the Kunxian Capsule group will take Kunxian Capsule 0.6gm orally twice daily for 24weeks</description>
    <arm_group_label>Kunxian capsule group</arm_group_label>
    <other_name>Tripterygium wilfordii Hook F.</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>the Methotrexate group will take Methotrexate 10mg orally every week for 24 weeks</description>
    <arm_group_label>Methotrexate group</arm_group_label>
    <other_name>jiaandieling</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients who understand the study protocol and sign the informed consent；

          2. Fulfill the 1987 or 2010 ACR classification criteria for RA；

          3. Male or female patients, age ranged from 40-70;

          4. Male or female who do not plan to have more child,or per-menopausal or menopausal
             women；

          5. Patients with mild or moderate disease activity, ie, whose DAS28 ranged from
             3.2-5.1（ie, ESR＞28mm/h，or patients who have 1-5 swollen joints as well as 1-5 tender
             joints）；

          6. Without severe systemic disorders,such as severe pericardial effusion,pulmonary
             interstitial fibrosis,renal tubual acidosis,atrophic gastritis,autoimmune liver
             disease etc.

          7. Not included in any drug trial 1 month before enrollment

        Exclusion Criteria:

          1. Pregnant woman or women who are preparing to pregnant or breast feeding；

          2. Patients with active liver diseases or elevated liver enzymes eg, the ALT and/or AST
             is higher than 1.5 of the upper limit of normal range;

          3. Patients with renal function abnormality,eg,serum creatinin higher than the upper
             limit of normal range；

          4. White blood cell count less than 3.0×109/L，or with anemia(hemoglobin level lower than
             80g/L），or platelet count less than 80×109/L，or with other hematological diseases;

          5. Patients with chronic gastrointestinal diseases；

          6. Patients with un-controlled hypertension,metabolic diseases such as diabetes;

          7. History of malignant tumor or has malignant tumor at present;

          8. With acute and/or chronic contagious diseases；

          9. Severe arrhythmia on ECG test;

         10. History of adverse reaction with Kunxian capsule,or Tripterygium wilfordii Hook
             F.,methotrexate or medications contain kunminshanhaitang ingredient；

         11. History of psychiatric diseases or alcoholism or drug abuse；

         12. Having been diagnosed to have systemic rheumatic diseases;

         13. Ever taken immunosuppressive agents or biological agents or Tripterygium wilfordii
             Hook F or medications contain kunminshanhaitang ingredient in recent 3 months；

         14. Had ever taken methotrexate or Kunxian capsule for more than 12 weeks but could not
             control the arthritis under remission；

         15. With other conditions that are considered to be inconsistent with the inclusion
             criteria according to the investigators.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>XIAOFENG ZENG, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking Union Medical College Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>XINPING TIAN, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking Union Medical College Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>XINPING TIAN, MD</last_name>
    <phone>86-10-69158707</phone>
    <email>tianxp6@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>HAIJUN FU, PHD</last_name>
    <phone>13601912507</phone>
    <email>hadrian.fox@shcares.com.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>the Affiliated Hospital to Bangbu Medical University</name>
      <address>
        <city>Bangbu</city>
        <state>Anhui</state>
        <zip>233000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhijun Li, MD</last_name>
      <phone>13955289810</phone>
      <email>zhijun.li@cstar.org.cn</email>
    </contact>
    <contact_backup>
      <last_name>Changhao Xie, MD</last_name>
      <phone>15255227208</phone>
      <email>uglboy2002@126.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Bengbu Medical College</name>
      <address>
        <city>Bengbu</city>
        <state>Anhui</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xin Wang, MD</last_name>
      <phone>86-13515529256</phone>
      <email>273084414@qq.com</email>
    </contact>
    <contact_backup>
      <last_name>Zhijun Li, MD</last_name>
      <phone>86-13956955150</phone>
      <email>lizhijundr@126.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>AnHui provincial hospital</name>
      <address>
        <city>Hefei</city>
        <state>Anhui</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Li Wang, MD</last_name>
      <phone>86-15055148790</phone>
      <email>wang_liy@aliyun.com</email>
    </contact>
    <contact_backup>
      <last_name>Xiangpei Li, MD</last_name>
      <phone>86-13515605909</phone>
      <email>13515605909@126.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Nanfang Hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jinjun Zhao, MD</last_name>
      <phone>86-13710596450</phone>
      <email>zhao7749@126.com</email>
    </contact>
    <contact_backup>
      <last_name>Min Yang, MD</last_name>
      <phone>86-13802911770</phone>
      <email>minyanggz@163.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>The Third Affiliated Hospital to SUN YAT-SEN University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Linkai Fang, MD</last_name>
      <phone>86-13751889563</phone>
      <email>fanglinkai1984@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Jieruo Gu, MD</last_name>
      <phone>13922280820</phone>
      <email>gujieruo@163.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Harbin Medcial University</name>
      <address>
        <city>Haerbin</city>
        <state>Heilongjiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juan Gao, MD</last_name>
      <phone>86-15304803480</phone>
      <email>happygigi@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Zhiyi Zhang, MD</last_name>
      <phone>86-13303608999</phone>
      <email>zhangzhiyi2014@163.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>The first affiliated hospital of Zhengzhou University</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jiameng Lu, MD</last_name>
      <phone>86-18637184930</phone>
      <email>lujiameng2003@126.com</email>
    </contact>
    <contact_backup>
      <last_name>Shengyun Liu, MD</last_name>
      <phone>86-13837192659</phone>
      <email>shengyun@medmail.com.cn</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Minda Hospital of Hubei Province</name>
      <address>
        <city>Enshi</city>
        <state>Hubei</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Linchong Su, MD</last_name>
      <phone>86-15571781515</phone>
      <email>&quot;linchongsu@126.com</email>
    </contact>
    <contact_backup>
      <last_name>Yang Xiang, MD</last_name>
      <phone>86-13607249969</phone>
      <email>xiangy1961@yahoo.com.cn</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Jiangsu Province Hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chengyin Li, MD</last_name>
      <phone>86-13914751367</phone>
      <email>lcyzjf@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Miaojia Zhang, MD</last_name>
      <phone>86-13611505999</phone>
      <email>miaojia_zhang@163.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Affiliated Hospital of Nantong University</name>
      <address>
        <city>Nantong</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yunfei Xia, MD</last_name>
      <phone>15896275028</phone>
      <email>xiayf1986@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Zhanyun Da, MD</last_name>
      <phone>86-18962940001</phone>
      <email>dazhanyun@163.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Xijing Hospital</name>
      <address>
        <city>Xian</city>
        <state>Shanxi</state>
        <zip>710032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhenbiao Wu, MD</last_name>
      <phone>13700235112</phone>
      <email>ping.zhu@cstar.org.cn</email>
    </contact>
    <contact_backup>
      <last_name>Weitong Chen, MD</last_name>
      <phone>15771943030</phone>
      <email>chenweitong0818@163.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>the Affiliated Hospital of Kunming Medical University</name>
      <address>
        <city>Kunming</city>
        <state>Yunnan</state>
        <zip>650032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jian Xu, MD</last_name>
      <phone>13888566797</phone>
      <email>jian.xu@cstar.org.cn</email>
    </contact>
    <contact_backup>
      <last_name>Shu Li, MD</last_name>
      <phone>15198785584</phone>
      <email>gglis@126.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Guang'anmen Hospital,China Academy of Chinese Medical Sciences</name>
      <address>
        <city>Beijing</city>
        <zip>100010</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hailong Wang, MD</last_name>
      <phone>86-13810112190</phone>
      <email>wang.hailong@139.com</email>
    </contact>
    <contact_backup>
      <last_name>Quan Jiang, MD</last_name>
      <phone>86-13901081632</phone>
      <email>doctorjq@126.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Peking Union Medical College Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xinping Tian, MD</last_name>
      <phone>86-13691165939</phone>
      <email>tianxp6@126.com</email>
    </contact>
    <contact_backup>
      <last_name>Shi Rong, MD</last_name>
      <phone>86-13601248311</phone>
      <email>rongshipumch@126.com</email>
    </contact_backup>
    <investigator>
      <last_name>XInping Tian, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Guang Hua hospital</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaolin Yang, MD</last_name>
      <phone>86-13701816768</phone>
      <email>lindayoung365@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Dongyi He, MD</last_name>
      <phone>021-62805833</phone>
      <email>dongyihe@medmail.com.cn</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Zhongshan Hospital Fudan University</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Huiyong Chen, MD</last_name>
      <phone>86-13817629793</phone>
      <email>zsneike@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Lindi Jiang, MD</last_name>
      <phone>86-13701973875</phone>
      <email>jianglindi@medmail.com.cn</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 26, 2016</study_first_submitted>
  <study_first_submitted_qc>May 4, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 6, 2016</study_first_posted>
  <last_update_submitted>March 8, 2017</last_update_submitted>
  <last_update_submitted_qc>March 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese SLE Treatment And Research Group</investigator_affiliation>
    <investigator_full_name>Xinping Tian</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Kunxian Capsule</keyword>
  <keyword>efficacy</keyword>
  <keyword>rheumatoid arthritis</keyword>
  <keyword>Methotrexate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

